| Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines BJ McMullan, D Andresen, CC Blyth, ML Avent, AC Bowen, PN Britton, ... The Lancet Infectious Diseases 16 (8), e139-e152, 2016 | 222 | 2016 |
| The long shadow of Lemierre’s syndrome J Osowicki, S Kapur, LK Phuong, S Dobson Journal of Infection 74, S47-S53, 2017 | 90 | 2017 |
| Increase in invasive group A streptococcal disease among Australian children coinciding with northern hemisphere surges YN Abo, J Oliver, A McMinn, J Osowicki, C Baker, JE Clark, CC Blyth, ... The Lancet Regional Health–Western Pacific 41, 2023 | 60 | 2023 |
| Decrease in infection-related hospital admissions during COVID-19: why are parents avoiding the doctor? S Kadambari, YN Abo, LK Phuong, J Osowicki, PA Bryant The Pediatric infectious disease journal 39 (11), e385-e386, 2020 | 56 | 2020 |
| Australia‐wide point prevalence survey of the use and appropriateness of antimicrobial prescribing for children in hospital J Osowicki, A Gwee, J Noronha, P Palasanthiran, B McMullan, PN Britton, ... Medical Journal of Australia 201 (11), 657-662, 2014 | 53 | 2014 |
| A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study J Osowicki, KI Azzopardi, L Fabri, HR Frost, T Rivera-Hernandez, ... The Lancet Microbe 2 (7), e291-e299, 2021 | 50 | 2021 |
| Australia-wide point prevalence survey of antimicrobial prescribing in neonatal units: how much and how good? J Osowicki, A Gwee, J Noronha, PN Britton, D Isaacs, TB Lai, C Nourse, ... The Pediatric infectious disease journal 34 (8), e185-e190, 2015 | 49 | 2015 |
| Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): establishing a group A Streptococcus pharyngitis human infection study J Osowicki, KI Azzopardi, C Baker, CS Waddington, M Pandey, T Schuster, ... Vaccine 37 (26), 3485-3494, 2019 | 45 | 2019 |
| Potential for molecular testing for group A Streptococcus to improve diagnosis and management in a high-risk population: a prospective study AP Ralph, DC Holt, S Islam, J Osowicki, DE Carroll, SYC Tong, AC Bowen Open Forum Infectious Diseases 6 (4), ofz097, 2019 | 41 | 2019 |
| Payment in challenge studies: ethics, attitudes and a new payment for risk model O Grimwade, J Savulescu, A Giubilini, J Oakley, J Osowicki, AJ Pollard, ... Journal of medical ethics 46 (12), 815-826, 2020 | 40 | 2020 |
| Immune signature of acute pharyngitis in a Streptococcus pyogenes human challenge trial J Anderson, S Imran, HR Frost, KI Azzopardi, S Jalali, B Novakovic, ... Nature Communications 13 (1), 769, 2022 | 39 | 2022 |
| WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: report from a meeting held on 12–13 December 2016 J Osowicki, J Vekemans, DC Kaslow, MH Friede, JH Kim, AC Steer Vaccine 36 (24), 3397-3405, 2018 | 38 | 2018 |
| A Controlled Human Infection Model of Group A Streptococcus Pharyngitis: Which Strain and Why? J Osowicki, KI Azzopardi, L McIntyre, T Rivera-Hernandez, CY Ong, ... Msphere 4 (1), 10.1128/msphere. 00647-18, 2019 | 30 | 2019 |
| A systematic review of human challenge trials, designs, and safety J Adams-Phipps, D Toomey, W Więcek, V Schmit, J Wilkinson, K Scholl, ... Clinical Infectious Diseases 76 (4), 609-619, 2023 | 29 | 2023 |
| Guillain‐Barré syndrome in an Australian state using both mRNA and adenovirus‐vector SARS‐CoV‐2 vaccines J Osowicki, H Morgan, A Harris, NW Crawford, JP Buttery, L Kiers Annals of Neurology 90 (5), 856, 2021 | 25 | 2021 |
| Global Streptococcus pyogenes strain diversity, disease associations, and implications for vaccine development: a systematic review PR Smeesters, G de Crombrugghe, SK Tsoi, C Leclercq, C Baker, ... The Lancet Microbe 5 (2), e181-e193, 2024 | 22 | 2024 |
| Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020, a meeting report AJ Pollard, R Sauerwein, M Baay, P Neels, S Balasingam, P Bejon, ... Biologicals 66, 41-52, 2020 | 19 | 2020 |
| Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy YN Abo, E Jamrozik, JS McCarthy, M Roestenberg, AC Steer, J Osowicki The Lancet Infectious Diseases 23 (12), e533-e546, 2023 | 16 | 2023 |
| Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia J Osowicki, HJ Morgan, A Harris, HJ Clothier, JP Buttery, L Kiers, ... Vaccine 40 (52), 7579-7585, 2022 | 15 | 2022 |
| Infliximab for paradoxical reactions in pediatric central nervous system tuberculosis YN Abo, N Curtis, J Osowicki, G Haeusler, R Purcell, S Kadambari, ... Journal of the Pediatric Infectious Diseases Society 10 (12), 1087-1091, 2021 | 15 | 2021 |
